Outcomes assessed | Total no of studies involved (n) | OR with 95% CI | P value | I2 value (%) |
---|---|---|---|---|
Major adverse cardiac events | 6 | 0.73 [0.59–0.91] | 0.005 | 35 |
All-cause mortality | 4 | 0.90 [0.48–1.68] | 0.74 | 0 |
Cardiac death | 5 | 0.56 [0.29–1.08] | 0.08 | 0 |
Myocardial infarction | 6 | 0.89 [0.62–1.27] | 0.53 | 37 |
Target vessel revascularization | 6 | 0.62 [0.43–0.89] | 0.01 | 21 |
Target lesion revascularization | 5 | 0.62 [0.45–0.85] | 0.003 | 0 |
Stent thrombosis | 5 | 0.72 [0.36–1.42] | 0.34 | 25 |